Clinical Trial Evaluating the Biological Activity of a New Drug Identified as Prifetrastat (PF-07248144), Combined With Fulvestrant for the Treatment of Patients With Hormone Receptor Positive (HR+) and HER2 Negative (HER2-) Breast Cancer Extended to Other Organs.

NCT07340619 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

51

Enrollment

OTHER

Sponsor class

Conditions

Metastatic (Stage IV) Melanoma

Interventions

DRUG: prifetrastat monotherapy for 15 days then combination with fulvestrant
DRUG: prifetrastat in combination with fulvestrant

Sponsor

UNICANCER

Collaborators

[object Object]